KIZ-Mutation Retinitis Pigmentosa: A Textbook Case for Gene Replacement Therapy
Retinitis pigmentosa gene therapy is not one-size-fits-all. Here is how to tell which genes are built for gene replacement, using KIZ, one cause of inherited retinitis pigmentosa, as a worked example.
When a family gets a genetic diagnosis of retinitis pigmentosa, the first question is usually "is there a therapy?" The more useful question is "what kind of therapy does this specific gene actually allow?" Not every form of retinitis pigmentosa is equally ready for every approach. Gene replacement therapy, where you deliver a fresh working copy of a gene into the patient's cells, works beautifully for some genes and poorly for others. The difference is not luck. It comes down to a short list of questions you can answer in advance, before a single dollar is spent on manufacturing.
KIZ-mutation retinitis pigmentosa answers almost all of those questions the right way. That is what makes it worth walking through. KIZ is a clean example of a gene that is, on paper, close to ideal for gene replacement. Here is why, and more importantly, here is the way of thinking that gets you to that conclusion for any retinitis pigmentosa gene, or any gene at all.
What gene replacement therapy is
Gene replacement therapy does not touch the broken copy of a gene. It delivers a new, functional copy alongside it, usually packaged inside an adeno-associated virus (AAV). The cell reads the new copy and starts making the protein it was missing. You are not editing anything. You are not silencing anything. You are restoring a part that was absent. In the eye, this is the same basic approach behind the first approved gene therapy for an inherited retinal disease, and it is one of the leading strategies in retinitis pigmentosa gene therapy today.
That mechanism sets the rules. Gene replacement is best suited to recessive, loss-of-function diseases, where the problem is simply "not enough working protein." It depends on being able to fit the gene inside the delivery vehicle. And like any therapy, it needs to reach the right cells while there are still cells worth saving. Hold those three ideas in mind, because KIZ satisfies all of them.
Factor one: the gene fits the truck
AAV is the workhorse of gene replacement, and it has a hard physical limit. The vector can carry roughly 4.7 kilobases of genetic cargo, and once you account for the promoter, regulatory elements, and the rest of the packaging, your usable space for the gene itself is smaller still. Plenty of important disease genes are simply too big to fit. That single constraint rules out a large fraction of gene replacement programs before they start, and it is why so much of the field is spent engineering workarounds like dual-vector delivery.
KIZ has no such problem. The gene that encodes the kizuna centrosomal protein has a coding sequence of only about 2 kilobases. That fits inside a single AAV with room to spare for a photoreceptor-specific promoter and the regulatory elements you want around it. There is no packaging puzzle to solve. The gene fits the truck, with cargo space left over.
Factor two: the disease moves, but not too fast
This is the factor people underestimate. Gene replacement preserves the cells you still have. It is not a resurrection. So the disease has to move slowly enough that, by the time you intervene, there is still living tissue to protect. But it also cannot move so slowly that you can never measure whether the therapy did anything. You are looking for a therapeutic window, a stretch of years where the patient is symptomatic, the target cells are still alive, and decline is measurable.
KIZ-mutation retinitis pigmentosa (RP69) sits within that window. It is a rod-cone dystrophy, the classic slow burn of inherited retinal disease and one of the reasons inherited retinal disease has become a leading area for gene therapy. In the small number of patients described so far, the course was recognizable: night blindness beginning in the late teens, then progressive midperipheral visual field loss, with full-field electroretinogram responses becoming undetectable, a marker of advanced disease, by around age 35. Later work documented progressive retinal pigment epithelium atrophy and photoreceptor death as the disease advances.
Read that natural history as a clock, and notice that it cuts both ways. The span between first symptoms and severe loss gives a real therapeutic window. A patient diagnosed early has years of viable photoreceptors that a one-time therapy could protect, and the earlier the intervention, the more there is to preserve. The same slow pace, though, is a challenge for a clinical trial. When a disease changes gradually, it takes longer, and more sensitive structural and functional measures, to demonstrate that a therapy has bent the curve. That tradeoff is worth being honest about. The point is not that a slower disease is simply better. It is that KIZ tends to progress fast enough to leave something to measure and slow enough to leave something to save, which is the range where intervention is most likely to matter.
Factor three: you can measure it with tools that already exist
A therapy is only as good as your ability to prove it worked, and regulators trust endpoints they already understand. The eye is one of the most measurable organs in medicine. For retinal degeneration there is an entire established toolkit: full-field electroretinography for photoreceptor function, visual field and perimetry testing for the area of usable vision, optical coherence tomography to track the ellipsoid zone and photoreceptor layer thickness structurally, microperimetry, full-field stimulus threshold testing, and functional measures of real-world navigation.
These are not speculative endpoints. They are the exact measures that supported the first FDA-approved gene replacement therapy for an inherited retinal disease, Luxturna (voretigene neparvovec), approved in 2017 for biallelic RPE65 disease, a condition that includes a retinitis pigmentosa presentation, with a multi-luminance mobility test as the primary endpoint and benefit sustained for years. For KIZ-mutation retinitis pigmentosa, you would not have to invent a way to measure success. You would reach for instruments the field has already validated.
The factor hiding underneath all of this: the genotype fits the strategy
There is one more reason KIZ is so well suited to this approach, and it is the quiet one. The disease-causing variants in KIZ are loss-of-function, including nonsense and frameshift mutations, and the disease is recessive. That is the genotype gene replacement was made for. You are not fighting a toxic mutant protein that has to be removed or corrected. The cell needs a working copy, and the strategy is to supply one.
The retina helps too. It is small, surgically accessible, and immune-privileged, which lowers the dose you need and the immune risk you carry. It even gives you a built-in control, because you can compare a treated eye against the untreated fellow eye in the same patient. The RPE65 program proved this whole class of target is tractable. KIZ shares its essential structure: a recessive, loss-of-function, retinally expressed gene, small enough to deliver.
The real point: KIZ scored well because we asked the right questions
It is tempting to read all of this and conclude that KIZ got lucky. It did not. KIZ looks compelling because we ran it through a structured evaluation and it happened to pass on every axis. The same set of questions applies to every gene, whether or not the answers come back favorable:
What is the genotype? Loss of function or gain of function, recessive or dominant, the kind of defect that augmentation can fix or the kind that demands editing or silencing.
What is the phenotype? How fast does the disease move, is there a therapeutic window, and which tissues are affected.
Which therapy fits? Whether the gene packages into a deliverable vector, and whether the modality matches the mutation.
Can you reach it, and can you measure it? Whether delivery to the relevant cells is feasible today, and whether validated endpoints exist to prove benefit.
Most genes fail at least one of these. Some are too large for AAV. Some sit in tissues we cannot yet deliver to. Some progress too fast to catch or too slowly to measure. The work, the part that actually saves families time and money, is running this triage honestly and early, so that a program is only built where the biology supports it. KIZ is the rare case where the answer is yes across the board.
What Nome does
This evaluation is exactly what Nome does, for any gene, across every modality, and we give the analysis away for free. We do not start from a preferred therapy and look for a reason to use it. We start from the patient's specific mutation and ask which approaches are genuinely feasible, gene replacement, gene editing, ASOs, drug repurposing, then map the fastest viable path to the right one. The KIZ-mutation retinitis pigmentosa program advanced by the Kizuna Foundation is one example of where that analysis came back pointing clearly at gene replacement therapy. For another family, even another family with retinitis pigmentosa, the same process might rule gene replacement out and point somewhere else entirely. That is the point. The honest answer depends on the gene.
The first step is always the same. Get a genetic diagnosis, then find out what is actually possible.
Submit a diagnosis for a free evaluation at nome.bio.
References
El Shamieh S, et al. Whole-exome sequencing identifies KIZ as a ciliary gene associated with autosomal-recessive rod-cone dystrophy. Am J Hum Genet. 2014. https://www.sciencedirect.com/science/article/pii/S0002929714001074
OMIM. Retinitis Pigmentosa 69 (RP69), #615780. https://www.omim.org/entry/615780
OMIM. Kizuna Centrosomal Protein (KIZ), *615757. https://www.omim.org/entry/615757
Lin Y, et al. Progressive RPE atrophy and photoreceptor death in KIZ-associated autosomal recessive retinitis pigmentosa. Ophthalmic Genet. 2020. https://pubmed.ncbi.nlm.nih.gov/32052671/
Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy. Drugs. 2020. https://pubmed.ncbi.nlm.nih.gov/32535767/
Russell S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849-860.